EGFR, epidermal growth factor receptor, 1956

N. diseases: 1394; N. variants: 183
Disease: Malignant neoplasm of lung ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE EGFR mutation status was not correlated with R497KEGFR genotype of lung cancers. 18726117 2009
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE One-hundred and fifty two patients with activating EGFR mutations were included in this study and 136 patients' tumor sample were available for targeted sequencing of genomic alterations in 22 genes using the Colon and Lung Cancer panel (Ampliseq, Life Technologies). 27121209 2016
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE We analyzed gene expression profiles of gefitinib-resistant PC9M2 cells that were derived from gefitinib-sensitive lung cancer PC9 cells and do not have known resistance mechanisms including EGFR mutation T790M. 26268703 2015
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE Mutations in the epidermal growth factor receptor gene (EGFR) in lung cancers predict for sensitivity to EGFR kinase inhibitors. 25326805 2014
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE About half of the Japanese patients with lung cancers harbor an activating mutation of the epidermal growth factor receptor gene and they are very sensitive to epidermal growth factor receptor tyrosine kinase inhibitors. 20031962 2010
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity. 24885886 2014
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE The results of our grouped testing approach with optimized biosensors were consistent with that of direct sequencing, suggesting that our proposed protocol can be excellent candidate for genotyping of EGFR mutations in lung cancer patients. 29245087 2018
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. 19898258 2010
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE In this study, we have investigated the erbB3 mRNA levels in reference to clinicopathologic data and EGFR mutation status in Japanese lung cancer specimens. 17631905 2008
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE Our observations show that EGFR-T790M provides a proliferative advantage with respect to WT EGFR and suggest that the enhanced kinase activity of this mutant is the basis for rare cases of inherited susceptibility to lung cancer. 17510392 2007
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE The EGFR mutation status, especially L858R mutation might be correlated with the clinico-pathological features related to good response to gefitinib, such as gender, smoking history, and pathological subtypes of Japanese lung cancers. 16890322 2006
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. 22982659 2012
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE Somatic mutations in the epidermal growth factor receptor (EGFR) occur frequently in lung cancer and confer sensitivity to EGFR kinase inhibitors gefitinib and erlotinib. 16540667 2006
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE Treatment of lung cancers harboring EGFR exon 20 insertions may therefore require the development of alternative kinase inhibition strategies. 16187797 2005
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. 24353160 2013
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE Interestingly, in an EGFR mutated lung cancer cell line, treatment with an EGFR inhibitor (Gefitinib) resulted in a concentration specific reduction in c-MYC and miR-9 expression while not changing let-7a expression. 23365639 2013
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE The use of a two-tiered testing strategy for the simultaneous detection of small EGFR mutations and EGFR amplification in lung cancer. 25719557 2015
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE The determination of EGFR mutations involves a change in the therapeutic approach to lung cancer patients in current clinical practice. 20678850 2011
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE An association of EGFR activating mutation with a family history of lung cancer in first-degree relatives was evaluated with multivariate logistic regression analysis, and its association with survival was estimated with Cox's proportional hazards model. 28486527 2017
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE It is concluded that EGFR exon 18-21 mutations are rare in Middle East patients with lung cancer and occur in a similar range as in Western patients. 16564920 2006
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations. 20406974 2010
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE Unfortunately, after an initial and sometimes durable benefit from EGFR-TKI therapy, all patients with EGFR-mutant lung cancer eventually become resistant to the treatment and experience disease progression. 28188446 2017
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE Brain metastasis (BM) is common in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer. 31634655 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE Genetic analysis suggested that the specific EGFR mutation L858R in exon 21 might be the main factor contributing to lung carcinogenesis in multiple lung cancers. 22733594 2012
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.600 GeneticVariation disease BEFREE First-generation tyrosine kinase inhibitors improve progression-free survival in lung cancers with epidermal growth factor receptor (EGFR) mutations. 23937608 2014